FDA Approves Tralokinumab for Moderate to Severe Eczema in Adolescents

The US Food and Drug Administration (FDA) today announced it has expanded the approval of tralokinumab-ldrm (Adbry) for treating moderate to severe atopic dermatitis (AD) in children 12-17 years old, according to a press release from the manufacturer, Leo Pharma. 

The therapy is for those whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advised. 

It is the first treatment for pediatric patients with moderate to severe AD that specifically targets the interleukin (IL)-13 cytokine, one of the key drivers of AD symptoms. Tralokinumab was first approved by the FDA in December 2021 for the same indication in adults. 

"It's so important to have treatment options with demonstrated efficacy in itch reduction and skin clearance," Amy Paller, MD, chair of the department of dermatology, Northwestern University, Chicago, said in the manufacturer's release. 

Source: MEDspace